• Vaccine Name: RPC4/DIMQ
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: RPC4 fusion protein, consisting of Rv2131c, Rv1984c, Rv2029c and Rv0388c.
• cysQ gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation(Wang et al., 2025).
  • Detailed Gene Information: Click Here.
• cfp21 gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein reparation(Wang et al., 2025).
  • Detailed Gene Information: Click Here.
• 6-phosphofructokinase PfkB gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation(Wang et al., 2025).
  • Detailed Gene Information: Click Here.
• Preparation: The RPC4 fusion protein was recombinantly expressed in Escherichia coli, purified by Ni-NTA affinity chromatography with endotoxin removal, and emulsified with the liposomal adjuvant DIMQ (DDA combined with imiquimod).(Wang et al., 2025)
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Host age: 6-9 weeks
• Host gender: Female
• Vaccination Protocol: Mice were primed with BCG at week 0 and boosted subcutaneously with the RPC4/DIMQ subunit vaccine every 3 weeks for a total of three booster immunizations, with immune responses assessed at week 9.(Wang et al., 2025)
• Immune Response: Vaccination with RPC4/DIMQ, particularly as a BCG prime boost regimen, induced strong Th1-biased immune responses characterized by elevated IFN-?, TNF-?, and IL-2 secretion, increased multifunctional CD4? and CD8? T cells, and high antigen-specific IgG2a antibody titers.(Wang et al., 2025)
• Information about this animal model: Mouse Model for TB research